Cargando…
Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease
Despite improvement in outcomes, loss of response (LOR) to tumor necrosis factor-alpha (TNFα) therapies is a big concern in the management of inflammatory bowel disease. LOR is associated with flares of disease, increased hospitalisation rates, need for surgical interventions, and decline in quality...
Autores principales: | Tighe, Donal, McNamara, Deirdre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291846/ https://www.ncbi.nlm.nih.gov/pubmed/28210077 http://dx.doi.org/10.3748/wjg.v23.i3.414 |
Ejemplares similares
-
TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
por: Altwegg, Romain, et al.
Publicado: (2014) -
Food as Treatment of Inflammatory Bowel Diseases
por: Maldonado-Contreras, Ana
Publicado: (2022) -
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
por: McCormack, Matthew D, et al.
Publicado: (2023) -
Inflammatory bowel disease and airway diseases
por: Vutcovici, Maria, et al.
Publicado: (2016) -
Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future
por: Viganò, Chiara, et al.
Publicado: (2021)